Concepts, Methods, and Practical Considerations of Meta-Analysis in Drug Development

References

• Antman, E., Lau, J., Kupelnick, B., Mosteller, F., and Chalmers, T. (1992), “A Comparison of Results of Meta-Analyses of Randomized Control Trials and Recommendations of Clinical Experts. Treatments for Myocardial Infarction,” The Journal of the American Medical Association, 268, 240–248.
   Google Scholar
• Bailey, K. R. (1987), “Inter-Study Differences: How Should They Influence the Interpretation and Analysis of Results?” Statistics in Medicine, 6, 351–358.
   Google Scholar
• Bennett, M. M., Crowe, B. J., Price, K. L., Stamey, J. D., and Seaman, Jr., J. W. (2013), “Comparison of Bayesian and Frequentist Meta-Analytical Approaches for Analyzing Time to Event Data,” Journal of Biopharmaceutical Statistics, 23, 129–145.
   Google Scholar
• Berkey, C., Anderson, J., and Hoaglin, D. (1996), “Multiple-Outcome Meta-Analysis of Clinical Trials,” Statistics in Medicine, 15, 537–557.
   Google Scholar
• Berkey, C., Hoaglin, D., Antczak-Bouckoms, A., and Colditz, G. (1998), “Meta-Analysis of Multiple Outcomes by Regression With Random Effects,” Statistics in Medicine, 17, 2537–2550.
   Google Scholar
• Berlin, J. A., Crowe, B. J., Whalen, E., Xia, H. A., Koro, C. E., and Kuebler, J. (2013), “Meta-Analysis of Clinical Trial Safety Data in a Drug Development Program: Answers to Frequently Asked Questions,” Clinical Trials, 10, 20–31.
   Google Scholar
• Borenstein, M., Hedges, L., and Rothstein, D. (2007), “Meta-Analysis: Fixed Effect vs. Random Effects,” available at http://www.meta-analysis.com/downloads/Meta-analysis_fixed_effect_vs_ra ndom_effects_sv.pdf.
   Google Scholar
• Borenstein, M., Hedges, L. V., Higgins, J. P. T., and Rothstein, H. R. (2009), Introduction to Meta-Analysis ( 1st ed.), New York: Wiley.
   Google Scholar
• Bradburn, M. J., Deeks, J. J., Berlin, J. A., and Russell Localio, A. (2007), “Much Ado About Nothing: A Comparison of the Performance of Meta-Analytical Methods With Rare Events,” Statistics in Medicine, 26, 53–77.
   Google Scholar
• Chuang-Stein, C., and Beltangady, M. (2011), “Reporting Cumulative Proportion of Subjects With an Adverse Event Based on Data From Multiple Studies,” Pharmaceutical Statistics, 10, 3–7.
   Google Scholar
• Coleman, R. L., Sill, M. W., Lankes, H. A., Fader, A. N., Finkler, N. J., Hoffman, J. S., Rose, P. G., Sutton, G. P., Drescher, C. W., McMeekin, D. S., Hu, W., Deavers, M., Godwin, A. K., Alpaugh, R. K., and Sood, A. K. (2012), “A Phase {II} Evaluation of Aflibercept in the Treatment of Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study,” Gynecologic Oncology, 127, 538–543.
   Google Scholar
• Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L., Buzenet, G., and Chamberlain, D. (2012), “A Phase {II} Study of Aflibercept in Patients With Advanced Epithelial Ovarian Cancer and Symptomatic Malignant Ascites,” Gynecologic Oncology, 125, 42–47.
   Google Scholar
• Cooper, H., Hedges, L. V., and Valentine, J. C. (2009), The Handbook of Research Synthesis and Meta-Analysis ( 2nd ed.), New York: Russell Sage Foundation.
   Google Scholar
• DerSimonian, R., and Laird, N. (1986), “Meta-Analysis in Clinical Trials,” Controlled Clinical Trials, 7, 177–188.
   Google Scholar
• Food and Drug Administration (2009), Guidance for Industry: Integrated Summarizes of Effectiveness and Safety: Location Within the Common Technical Document, Silver Spring, MD: Food and Drug Administration.
   Google Scholar
• Gaynor, P., McCarberg, B., Zheng, W., Shoemaker, S., and Duenas, H. (2011), “Weight Change With Long-Term Duloxetine Use in Chronic Painful Conditions: An Analysis of 16 Clinical Studies,” International Journal of Clinical Practice, 65, 341–349.
   Google Scholar
• Gotlieb, W. H., Amant, F., Advani, S., Goswami, C., Hirte, H., Provencher, D., Somani, N., Yamada, S. D., Tamby, J.-F., and Vergote, I. (2012), “Intravenous Aflibercept for Treatment of Recurrent Symptomatic Malignant Ascites in Patients With Advanced Ovarian Cancer: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study,” The Lancet Oncology, 13, 154–162.
   Google Scholar
• Higgins, J., and Green, S. (2011), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] ( 2nd ed.), The Cochrane Collaboration. Available at www.cochranehandbook.org.
   Google Scholar
• Jennison, C., and Turnbull, B. W. (2005), “Meta-Analyses and Adaptive Group Sequential Designs in the Clinical Development Process,” Journal of Biopharmaceutical Statistics, 15, 537–558.
   Google Scholar
• Leighl, N. B., Raez, L. E., Besse, B., Rosen, P. J., Barlesi, F., Massarelli, E., Gabrail, N., Hart, L. L., Albain, K. S., Berkowitz, L., Melnyk, O., Shepherd, F. A., Sternas, L., Ackerman, J., Shun, Z., Miller, V. A., and Herbst, R. S. (2010), “A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung,” Journal of Thoracic Oncology, 5, 1054–1059.
   Google Scholar
• Light, R. J., and Pillemer, D. B. (1984), Summing Up, Cambridge, MA: Harvard University Press.
   Google Scholar
• Lièvre, M., Cucherat, M., and Leizorovicz, A. (2002), “Pooling, Meta-Analysis, and the Evaluation of Drug Safety,” Current Controlled Trials in Cardiovascular Medicine, 3, doi:10.1186/1468-6708-3-6.
   Google Scholar
• Lumley, T. (2002), “Network Meta-Analysis for Indirect Treatment Comparisons,” Statistics in Medicine, 21, 2313–2324.
   Google Scholar
• Mackay, H., Buckanovich, R., Hirte, H., Correa, R., Hoskins, P., Biagi, J., Martin, L., Fleming, G., Morgan, R., Wang, L., Polintan, R., and Oza, A. (2012), “A Phase {II} Study Single Agent of Aflibercept (vegf Trap) in Patients With Recurrent or Metastatic Gynecologic Carcinosarcomas and Uterine Leiomyosarcoma. A Trial of the Princess Margaret Hospital, Chicago and California Cancer Phase {II} Consortia,” Gynecologic Oncology, 125, 136–140.
   Google Scholar
• Nissen, S. E., and Wolski, K. (2007), “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death From Cardiovascular Causes,” New England Journal of Medicine, 356, 2457–2471.
   Google Scholar
• Peto, R. (1987), “Why Do We Need Systematic Overviews of Randomized Trials? (Transcript of an Oral Presentation, Modified by the Editors),” Statistics in Medicine, 6, 233–240.
   Google Scholar
• Qi, W., Tang, L., Shen, Z., and Yao, Y. (2014), “Treatment-Related Mortality With Aflibercept in Cancer Patients: A Meta-Analysis,” European Journal of Clinical Pharmacology, 70, 461–467.
   Google Scholar
• Quan, H., Ma, Y., Zheng, Y., Cho, M., Lorenzato, C., and Hecquet, C. (2015), “Adaptive and Repeated Cumulative Meta-Analyses of Safety Data During a New Drug Development Process,” Pharmaceutical Statistics, 14, 161–171.
   Google Scholar
• Ramlau, R., Gorbunova, V., Ciuleanu, T. E., Novello, S., Ozguroglu, M., Goksel, T., Baldotto, C., Bennouna, J., Shepherd, F. A., Le-Guennec, S., Rey, A., Miller, V., Thatcher, N., and Scagliotti, G. (2012), “Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Nonsmall-Cell Lung Cancer: A Randomized, Controlled Phase III Trial,” Journal of Clinical Oncology, 30, 3640–3647.
   Google Scholar
• Rougier, P., Riess, H., Manges, R., Karasek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., and Philip, P. A. (2013), “Randomised, Placebo-Controlled, Double-Blind, Parallel-Group Phase {III} Study Evaluating Aflibercept in Patients Receiving First-Line Treatment With Gemcitabine for Metastatic Pancreatic Cancer,” European Journal of Cancer, 49, 2633–2642.
   Google Scholar
• Sherman, E. J., Ho, A. L., Haque, S., Ghossein, R. A., Lisa, D. M., Schöder, H., Baum, M. S., Shaha, A. R., Tuttle, R. M., and Pfister, D. G. (2010), “A Phase ii Study of VEGF Trap (Aflibercept) in Patients With Radioactive Iodine-Refractory, Positron Emission Tomography (pet) Positive Thyroid Carcinoma,” Journal of Clinical Oncology, 28.
   Google Scholar
• Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A., and Song, F. (2000), Methods for Meta-Analysis in Medical Research ( 1st ed.), New York: Wiley.
   Google Scholar
• Sutton, A. J., Cooper, N. J., Lambert, P. C., Jones, D. R., Abrams, K. R., and Sweeting, M. J. (2002), “Meta-Analysis of Rare and Adverse Event Data,” Expert Review of Pharmacoeconomics and Outcomes Research, 2, 367–379.
   Google Scholar
• Sweeting, M. J., Sutton, A. J., and Lambert, P. C. (2004), “What to Add to Nothing? Use and Avoidance of Continuity Corrections in Meta-Analysis of Sparse Data,” Statistics in Medicine, 23, 1351–1375.
   Google Scholar
• Tabernero, J., Hitier, S., Derobert, E., and Van Cutsem, E. (2014), “Treatment-Related Mortality With Aflibercept in Cancer Patients,” European Journal of Clinical Pharmacology, 70, 1269–1270.
   Google Scholar
• Tang, P. A., Cohen, S. J., Kollmannsberger, C., Bjarnason, G., Virik, K., MacKenzie, M. J., Lourenco, L., Wang, L., Chen, A., and Moore, M. J. (2012), “Phase ii Clinical and Pharmacokinetic Study of Aflibercept in Patients With Previously Treated Metastatic Colorectal Cancer,” Clinical Cancer Research, 18, 6023–6031.
   Google Scholar
• Tannock, I. F., Fizazi, K., Ivanov, S., Karlsson, C. T., Flchon, A., Skoneczna, I., Orlandi, F., Gravis, G., Matveev, V., Bavbek, S., Gil, T., Viana, L., Arn, O., Karyakin, O., Elliott, T., Birtle, A., Magherini, E., Hatteville, L., Petrylak, D., Tombal, B., and Rosenthal, M. (2013), “Aflibercept Versus Placebo in Combination With Docetaxel and Prednisone for Treatment of Men With Metastatic Castration-Resistant Prostate Cancer (Venice): A Phase 3, Double-Blind Randomised Trial,” The Lancet Oncology, 14, 760–768.
   Google Scholar
• Thompson, S. G. (1994), “Systematic Review: Why Sources of Heterogeneity in Meta-Analysis Should be Investigated,” British Medical Journal, 309, 1351–1355.
   Google Scholar
• Tian, L., Cai, T., Pfeffer, M. A., Piankov, N., Cremieux, P.-Y., and Wei, L. J. (2009), “Exact and Efficient Inference Procedure for Meta-Analysis and Its Application to the Analysis of Independent 2 × 2 Tables With All Available Data But Without Artificial Continuity Correction,” Biostatistics, 10, 275–281.
   Google Scholar
• Webster, A., Playford, E., Higgins, G., Chapman, J., and Craig, J. (2004), “Interleukin 2 Receptor Antagonists for Kidney Transplant Recipients,” Cochrane Database of Systematic Reviews, Article CD003897, doi:10.1002/14651858.CD003897.pub2.
   Google Scholar